Visit us at booth #1243 to connect with our team and learn more about our Prosigna Breast Cancer Assay.

We have a variety of activities planned, including expert-led focused medical discussions at our booth and poster sessions.  See our schedule of activities below:

Focused Medical Discussions – New Data for Gene Expression Tests

WEDNESDAY, DECEMBER 11

• 12:30 PM CT

Preoperative endocrine therapy and the NeoTAILOR trial

Presented by: Prof. Nusayba Bagegni, St. Louis, Missouri

• 1:00 PM CT

OPTIMA – Trials updates

Presented by: Kelly Marcom, Medical Director, Veracyte

• 3:00 PM CT

Prosigna’s impact on risk stratification in HR+/HER2- EBC: a real-world comparison with OncotypeDX 

Presented by: Dr. Nicola Fusco and Dr. Giulia Cursano, IEO, Milan

• 5:30 PM CT

How is Prosigna utilised in the United Kingdom? Findings from a multi-centre RWE study 

Presented by: Dr. Thiraviyam Elumalai, Cambridge University

THURSDAY, DECEMBER 12

• 12:30 PM CT

Intrinsic subtype at progression to CDK4/6 inhibitors plus endocrine therapy in HR+/HER2- metastatic breast cancer

Presented by: Dr. Francesco Schettini, Hospital Clinic, Barcelona

• 1:00 PM CT

Experience with Prosigna assay from a tertiary hospital in Spain

Presented by: Dr. Rodrigo Sánchez Bayona, Hospital 12 de octubre, Madrid

• 1:30 PM CT

Performance of Genomic Assays in Diverse Populations

Presented by: Prof. Melissa Troester, Carolina Breast Cancer Study, University North Carolina

• 3:00 PM CT

Unlocking the potential of Prosigna-based trial designs in personalized breast cancer therapeutics    

Presented by: Dr. Tomás Pascual, Hospital Clinic, Barcelona

• 5:30 PM CT

Retrospective Analysis of different gene expression tests in HR+/HER2- breast cancer: correlation of Prosigna with EndoPredict and MammaPrint

Presented by: Brigitte Schober, Feldkirch, Austria

Poster Sessions

• Intrinsic Subtype at Progression to CDK4/6 Inhibitors Plus Endocrine Therapy in HormonReceptor-Positive/HER2-Negative Metastatic Breast Cancer (MBC)​

Presented by: Francesco Schettini (Spain)

Abstract Number: SESS-1016

• Comparison of different gene expression tests in breast cancer: poor correlation of Prosigna, EndoPredict and MammaPrint​

Presented by: Brigitte Schober

Abstract Number: SESS-1674

• Enhancing Risk Stratification in HR + Early Breast Cancer: A Real-World Evaluation of Oncotype Dx and Prosigna ​

Presented by: Nicola Fusco (Italy)

Abstract Number: SESS-1851

• Evaluating the Impact of Prosigna® Testing on Adjuvant Chemotherapy Decisions in Early-Stage ER-Positive, HER2-Negative Breast Cancer: A UK Study Thiraviyam Elumalai

Presented by: Thiraviyam Elumalai (UK) ​

Abstract Number: P1-10-12​

We look forward to seeing you in San Antonio.  If you would like to set up a meeting or have questions about Prosigna Get In Touch